Through our Clinical & Preclinical Investigator Initiated Studies program, we support investigators who have an interest in further exploring and gaining new and valuable information about the use of ibrutinib. Investigators and their sponsoring institution independently generate and submit a research proposal to our joint clinical or preclinical review committee, and assume all sponsor responsibilities if the study is approved.